celecoxib has been researched along with Pyrexia in 23 studies
| Excerpt | Relevance | Reference |
|---|---|---|
| "A 32-year-old man presented with pyrexia after 17 days of celecoxib therapy, which was reintroduced following 3-day total drug cessation." | 9.22 | Celecoxib-induced drug fever: A rare case report and literature review. ( Jia, SJ; Wu, CF; Xiao, J, 2022) |
| "Lornoxicam exhibits strong analgesic but weak antipyretic effects in rats with paw inflammation." | 7.75 | The importance of brain PGE2 inhibition versus paw PGE2 inhibition as a mechanism for the separation of analgesic and antipyretic effects of lornoxicam in rats with paw inflammation. ( Arai, I; Futaki, N; Harada, M; Hashimoto, Y; Honma, Y; Hoshi, K; Nakaike, S; Sugimoto, M, 2009) |
| "It was previously shown that sustained fever can be induced in rats by central injection of endothelin-1 (ET-1)." | 7.73 | The effects of selective and nonselective cyclooxygenase inhibitors on endothelin-1-induced fever in rats. ( Cristofoletti, R; Fabricio, AS; Navarra, P; Souza, GE; Veiga, FH, 2005) |
| "A 32-year-old man presented with pyrexia after 17 days of celecoxib therapy, which was reintroduced following 3-day total drug cessation." | 5.22 | Celecoxib-induced drug fever: A rare case report and literature review. ( Jia, SJ; Wu, CF; Xiao, J, 2022) |
| " Thus, physiological and pathophysiological roles of COX-2 were considered from the standpoint of clinical effects of the two latest COX-2 selective inhibitors, celecoxib and rofecoxib, on inflammation, pain, fever and colorectal cancer together with their adverse effects on gastrointestinal, renal and platelet functions; and the usefulness and limits of COX-2-selective inhibitors were discussed with the trends of new NSAIDs development." | 4.81 | [Cyclooxygenase (COX)-2 selective inhibitors: aspirin, a dual COX-1/COX-2 inhibitor, to COX-2 selective inhibitors]. ( Nakamura, H, 2001) |
| "Lornoxicam exhibits strong analgesic but weak antipyretic effects in rats with paw inflammation." | 3.75 | The importance of brain PGE2 inhibition versus paw PGE2 inhibition as a mechanism for the separation of analgesic and antipyretic effects of lornoxicam in rats with paw inflammation. ( Arai, I; Futaki, N; Harada, M; Hashimoto, Y; Honma, Y; Hoshi, K; Nakaike, S; Sugimoto, M, 2009) |
| "It was previously shown that sustained fever can be induced in rats by central injection of endothelin-1 (ET-1)." | 3.73 | The effects of selective and nonselective cyclooxygenase inhibitors on endothelin-1-induced fever in rats. ( Cristofoletti, R; Fabricio, AS; Navarra, P; Souza, GE; Veiga, FH, 2005) |
| "Celecoxib abrogated carrageenan-induced hyperalgesia in the hind paw accompanied by a decrease in PGE2 content in paw exudates and cerebrospinal fluid in a dose-related manner, with an ED30 = 0." | 1.33 | Pharmacological profile of celecoxib, a specific cyclooxygenase-2 inhibitor. ( Fukunaga, M; Hayashi, A; Kimoto, A; Kobayashi, S; Miyata, K; Noguchi, M; Sasamata, M; Yoshino, T, 2005) |
| "Patients presented with an exanthema and in most cases an edema of the face." | 1.32 | [Adverse cutaneous reaction to celecoxib: 6 cases]. ( Bocquet, H; Cosnes, A; Fischer, RM; Lelouet, H; Murr, D; Revuz, J, 2003) |
| "Celecoxib is a non-steroidal anti-inflammatory drug (NSAID) which acts via specific inhibition of cyclooxygenase-2 (synthesis of prostaglandins mediating pathological inflammation) but which preserves the homeostatic action of cyclooxygenase-1." | 1.32 | [Hypersensitivity to celecoxib]. ( Chiffoleau, A; Fradet, G; Huguenin, H; Robin-Le Nechet, A, 2003) |
| " Both exhibit good oral bioavailability and are potent in standard models of pain, fever, and inflammation yet have a much reduced effect on the GI integrity of rats compared to standard nonsteroidal antiflammatory drugs." | 1.30 | 2,3-Diarylcyclopentenones as orally active, highly selective cyclooxygenase-2 inhibitors. ( Black, WC; Brideau, C; Chan, CC; Charleson, S; Chauret, N; Claveau, D; Ethier, D; Gordon, R; Greig, G; Guay, J; Hughes, G; Jolicoeur, P; Leblanc, Y; Nicoll-Griffith, D; Ouimet, N; Prasit, P; Riendeau, D; Visco, D; Wang, Z; Xu, L, 1999) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (4.35) | 18.2507 |
| 2000's | 16 (69.57) | 29.6817 |
| 2010's | 5 (21.74) | 24.3611 |
| 2020's | 1 (4.35) | 2.80 |
| Authors | Studies |
|---|---|
| Black, WC | 2 |
| Brideau, C | 2 |
| Chan, CC | 2 |
| Charleson, S | 2 |
| Chauret, N | 1 |
| Claveau, D | 1 |
| Ethier, D | 1 |
| Gordon, R | 2 |
| Greig, G | 1 |
| Guay, J | 1 |
| Hughes, G | 2 |
| Jolicoeur, P | 1 |
| Leblanc, Y | 1 |
| Nicoll-Griffith, D | 1 |
| Ouimet, N | 1 |
| Riendeau, D | 2 |
| Visco, D | 1 |
| Wang, Z | 2 |
| Xu, L | 1 |
| Prasit, P | 2 |
| Puig, C | 1 |
| Crespo, MI | 1 |
| Godessart, N | 1 |
| Feixas, J | 1 |
| Ibarzo, J | 1 |
| Jiménez, JM | 1 |
| Soca, L | 1 |
| Cardelús, I | 1 |
| Heredia, A | 1 |
| Miralpeix, M | 1 |
| Puig, J | 1 |
| Beleta, J | 1 |
| Huerta, JM | 1 |
| López, M | 1 |
| Segarra, V | 1 |
| Ryder, H | 1 |
| Palacios, JM | 1 |
| Cromlish, W | 1 |
| Grimm, EL | 1 |
| Leger, S | 1 |
| Li, CS | 1 |
| Thérien, M | 1 |
| Xu, LJ | 1 |
| Eissa, AA | 1 |
| Farag, NA | 1 |
| Soliman, GA | 1 |
| Xiao, J | 1 |
| Jia, SJ | 1 |
| Wu, CF | 1 |
| Bastos-Pereira, AL | 2 |
| Fraga, D | 2 |
| Dreifuss, AA | 1 |
| Zampronio, AR | 2 |
| Blazeby, JM | 1 |
| Hall, E | 1 |
| Aaronson, NK | 1 |
| Lloyd, L | 1 |
| Waters, R | 1 |
| Kelly, JD | 1 |
| Fayers, P | 1 |
| Macciò, A | 1 |
| Gramignano, G | 1 |
| Madeddu, C | 1 |
| Leite, MC | 1 |
| Soares, DM | 5 |
| Machado, RR | 3 |
| Yamashiro, LH | 1 |
| Melo, MC | 1 |
| Souza, GE | 4 |
| Palma, BD | 1 |
| Nobrega, JN | 1 |
| Gomes, VL | 1 |
| Esumi, LA | 1 |
| Seabra, ML | 1 |
| Tufik, S | 1 |
| Hipolide, DC | 1 |
| Kanashiro, A | 1 |
| Pessini, AC | 1 |
| Malvar, Ddo C | 2 |
| Aguiar, FA | 1 |
| do Vale, ML | 1 |
| de Souza, GE | 1 |
| Futaki, N | 1 |
| Harada, M | 1 |
| Sugimoto, M | 1 |
| Hashimoto, Y | 1 |
| Honma, Y | 1 |
| Arai, I | 1 |
| Nakaike, S | 1 |
| Hoshi, K | 1 |
| Martins, JM | 1 |
| Longhi-Balbinot, DT | 1 |
| Figueiredo, MJ | 1 |
| de Melo, MC | 1 |
| Rae, GA | 1 |
| Murr, D | 1 |
| Bocquet, H | 1 |
| Lelouet, H | 1 |
| Fischer, RM | 1 |
| Revuz, J | 1 |
| Cosnes, A | 1 |
| Burdan, F | 1 |
| Korobowicz, A | 1 |
| Fradet, G | 1 |
| Robin-Le Nechet, A | 1 |
| Huguenin, H | 1 |
| Chiffoleau, A | 1 |
| Fabricio, AS | 1 |
| Veiga, FH | 1 |
| Cristofoletti, R | 1 |
| Navarra, P | 1 |
| Yoshino, T | 1 |
| Kimoto, A | 1 |
| Kobayashi, S | 1 |
| Noguchi, M | 1 |
| Fukunaga, M | 1 |
| Hayashi, A | 1 |
| Miyata, K | 1 |
| Sasamata, M | 1 |
| Okumura, T | 1 |
| Murata, Y | 1 |
| Hizue, M | 1 |
| Matsuura, T | 1 |
| Naganeo, R | 1 |
| Kanai, Y | 1 |
| Murase, A | 1 |
| Sakakibara, A | 1 |
| Fujita, I | 1 |
| Nakao, K | 1 |
| Hilário, MO | 1 |
| Terreri, MT | 1 |
| Len, CA | 1 |
| Proudfoot, AE | 1 |
| Nakamura, H | 1 |
4 reviews available for celecoxib and Pyrexia
| Article | Year |
|---|---|
Celecoxib-induced drug fever: A rare case report and literature review.
Topics: Adult; Anti-Inflammatory Agents, Non-Steroidal; Celecoxib; Cyclooxygenase 2 Inhibitors; Fever; Human | 2022 |
[Coxibs: highly selective cyclooxygenase-2 inhibitors. Part I. Clinical efficacy].
Topics: Alzheimer Disease; Celecoxib; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Cyclooxygenase Inhibito | 2003 |
Nonsteroidal anti-inflammatory drugs: cyclooxygenase 2 inhibitors.
Topics: Adolescent; Aspirin; Celecoxib; Child; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Drug Interacti | 2006 |
[Cyclooxygenase (COX)-2 selective inhibitors: aspirin, a dual COX-1/COX-2 inhibitor, to COX-2 selective inhibitors].
Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Celecoxib; Clinical Trials as Topic; Colo | 2001 |
1 trial available for celecoxib and Pyrexia
| Article | Year |
|---|---|
Validation and reliability testing of the EORTC QLQ-NMIBC24 questionnaire module to assess patient-reported outcomes in non-muscle-invasive bladder cancer.
Topics: Adult; Aged; Aged, 80 and over; Anxiety; Celecoxib; Combined Modality Therapy; Cyclooxygenase 2 Inhi | 2014 |
18 other studies available for celecoxib and Pyrexia
| Article | Year |
|---|---|
2,3-Diarylcyclopentenones as orally active, highly selective cyclooxygenase-2 inhibitors.
Topics: Analgesics, Non-Narcotic; Animals; Arthritis, Experimental; Biological Availability; Carrageenan; Ce | 1999 |
Synthesis and biological evaluation of 3,4-diaryloxazolones: A new class of orally active cyclooxygenase-2 inhibitors.
Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Arthritis, Experimental; Cyclooxygenase Inhibitors | 2000 |
3,4-Diaryl-5-hydroxyfuranones: highly selective inhibitors of cyclooxygenase-2 with aqueous solubility.
Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Arthritis, Experimental; Chemical Phenomena; Chemi | 2003 |
Synthesis, biological evaluation and docking studies of novel benzopyranone congeners for their expected activity as anti-inflammatory, analgesic and antipyretic agents.
Topics: Analgesics, Non-Narcotic; Animals; Anti-Inflammatory Agents, Non-Steroidal; Benzopyrans; Catalytic D | 2009 |
Central mediators of the zymosan-induced febrile response.
Topics: Animals; Body Temperature; Celecoxib; Dinoprostone; Fever; Indomethacin; Infusions, Intraventricular | 2017 |
Surprising results of a supportive integrated therapy in myelofibrosis.
Topics: Anemia; C-Reactive Protein; Cachexia; Carnitine; Celecoxib; Curcumin; Erythropoietin; Fatigue; Ferri | 2015 |
Central mediators involved in the febrile response induced by polyinosinic-polycytidylic acid: lack of involvement of endothelins and substance P.
Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Antibodies; Body Temperature; Celecoxib; Central N | 2015 |
Cytokine-induced neutrophil chemoattractant (CINC)-1 induces fever by a prostaglandin-dependent mechanism in rats.
Topics: Analysis of Variance; Animals; Anti-Inflammatory Agents, Non-Steroidal; Body Temperature; Celecoxib; | 2008 |
Prostaglandin involvement in hyperthermia induced by sleep deprivation: a pharmacological and autoradiographic study.
Topics: Animals; Autoradiography; Body Temperature; Celecoxib; Cyclooxygenase Inhibitors; Dinoprostone; Feve | 2009 |
Characterization and pharmacological evaluation of febrile response on zymosan-induced arthritis in rats.
Topics: Acetaminophen; Analgesics, Non-Narcotic; Animals; Arthritis, Experimental; Body Temperature; Celecox | 2009 |
The importance of brain PGE2 inhibition versus paw PGE2 inhibition as a mechanism for the separation of analgesic and antipyretic effects of lornoxicam in rats with paw inflammation.
Topics: Administration, Oral; Animals; Anti-Inflammatory Agents, Non-Steroidal; Arthritis, Experimental; Cel | 2009 |
Involvement of PGE2 and RANTES in Staphylococcus aureus-induced fever in rats.
Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Ascitic Fluid; Celecoxib; Chemokine CCL5; Cyclooxy | 2012 |
[Adverse cutaneous reaction to celecoxib: 6 cases].
Topics: Anti-Inflammatory Agents, Non-Steroidal; Celecoxib; Exanthema; Female; Fever; Humans; Hypersensitivi | 2003 |
[Hypersensitivity to celecoxib].
Topics: Aged; Anti-Inflammatory Agents, Non-Steroidal; Celecoxib; Chemical and Drug Induced Liver Injury; Dr | 2003 |
The effects of selective and nonselective cyclooxygenase inhibitors on endothelin-1-induced fever in rats.
Topics: Animals; Celecoxib; Cyclooxygenase Inhibitors; Diclofenac; Dinoprost; Dinoprostone; Dose-Response Re | 2005 |
Pharmacological profile of celecoxib, a specific cyclooxygenase-2 inhibitor.
Topics: Animals; Carrageenan; Celecoxib; Cyclooxygenase 1; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Cy | 2005 |
Pharmacological separation between peripheral and central functions of cyclooxygenase-2 with CIAA, a novel cyclooxygenase-2 inhibitor.
Topics: Animals; Brain; Carrageenan; Celecoxib; Chlorobenzoates; Cyclooxygenase 1; Cyclooxygenase 2; Cycloox | 2006 |
CCR1 and CCR5 chemokine receptors are involved in fever induced by LPS (E. coli) and RANTES in rats.
Topics: Analysis of Variance; Animals; Body Temperature; Celecoxib; Chemokine CCL5; Cyclooxygenase Inhibitor | 2007 |